Evaluation of the Effectiveness of the Risk Minimization Measures of Sodium Oxybate in the European Union
Abstract Background Sodium oxybate (Xyrem®), approved by the European Medicines Agency (EMA) for narcolepsy with cataplexy, is only available through risk mitigation programs due to potential adverse effects including respiratory and central nervous system depression, neuropsychiatric events, and mi...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Book |
| Published: |
Adis, Springer Healthcare,
2020-09-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Internet
Connect to this object online.3rd Floor Main Library
| Call Number: |
A1234.567 |
|---|---|
| Copy 1 | Available |